Loading data for KRYS — first visit, this takes a few seconds.

Alert

Krystal Biotech Inc. (KRYS)

NasdaqGS: KRYS · Real-Time Price · USD

346.58

+9.56 (2.84%)

At close: Aug 21, 2026, 8:00 PM

The price, the headline numbers and the latest news, in one place.

2.84% (1D)

No data available

Bid	335.08
Market Cap	10.26B
Revenue (ttm)	440.48M
Net Income (ttm)	241.46M
	0.54
	7.97
	43.49
	36.88
P/B (ttm)	7.99
P/S (ttm)	23.29
Earnings Date	Nov 2, 2026

Ask	332.34
Volume	407,790
Avg. Volume (20D)	413,543
Open	337.44
Previous Close	337.02
Day's Range	335.72 - 347.92
52-Week Range	136.73 - 382.54
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 20, 2017

Employees 295

Stock Exchange NasdaqGS

Ticker Symbol KRYS

Website https://www.krystalbio.com

Full Company Profile

Financial Performance

In 2025, Krystal Biotech's revenue was 389.13M, an increase of 33.94% compared to the previous year's 290.51M. Earnings were 204.83M, an increase of 129.74%.

Financial Statements

Earnings Surprise

Krystal Biotech has released their quarterly earnings on Aug 3, 2026:

Revenue of $119.22M misses estimates by $0, with 24.14% YoY growth.
EPS of 1.79 misses estimates by -0.12, with 38.76% YoY growth.

Next Earnings Release

Krystal Biotech Inc. is scheduled to release its earnings on Nov 2, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · MT Newswires

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis

1 week ago · 24/7 Wall St.

Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, ...

2 weeks ago · Motley Fool

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript

VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.

2 weeks ago · Simply Wall St.

Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run

Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectatio...

3 weeks ago · Zacks

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Page 1 of 2

Krystal Biotech Inc. (KRYS)